Drugs / BARS13
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04851977 | Oct 2018 → Apr 2019 | respiratory syncytial virus infectious disease | Advaccine (Suzhou) Biopharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04681833 | May 2021 → Jan 2024 | respiratory syncytial virus infectious disease | Advaccine (Suzhou) Biopharmaceuticals Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BARS13 | “The investigational product BARS13 has not previously been administered to human subjects.” NCT04851977 ↗ |
| Modality | Vaccine | “Advaccine Clinical Research is developing a recombinant Respiratory Syncytial Virus (rRSV) vaccine - BARS13 for the protection of the elderly from RSV infection.” NCT04681833 ↗ |
| Route | Intramuscular | “administered by IM injection to the deltoid region” NCT04681833 ↗ |